BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 24378831)

  • 1. Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS.
    Walter I; Wolfesberger B; Miller I; Mair G; Burger S; Gallè B; Steinborn R
    Oncol Rep; 2014 Mar; 31(3):1147-56. PubMed ID: 24378831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
    Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
    Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGFR, RET, and RAF/MEK/ERK pathway take part in the inhibition of osteosarcoma MG63 cells with sorafenib treatment.
    Mei J; Zhu X; Wang Z; Wang Z
    Cell Biochem Biophys; 2014 May; 69(1):151-6. PubMed ID: 24375110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
    Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
    Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
    Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
    Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
    Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Wnt pathway, uPA, PAI-1, MT1-MMP, S100A4 and CXCR4 associated with enhanced metastasis of human large cell lung cancer by DNA microarray.
    Qiu X; Guo S; Wu H; Chen J; Zhou Q
    Minerva Med; 2012 Jun; 103(3):151-64. PubMed ID: 22653095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
    Ruan M; Liu M; Dong Q; Chen L
    J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
    Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
    Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer.
    Sack U; Walther W; Scudiero D; Selby M; Kobelt D; Lemm M; Fichtner I; Schlag PM; Shoemaker RH; Stein U
    J Natl Cancer Inst; 2011 Jul; 103(13):1018-36. PubMed ID: 21685359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
    Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
    Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small interfering RNA-directed knockdown of S100A4 decreases proliferation and invasiveness of osteosarcoma cells.
    Ma X; Yang Y; Wang Y; An G; Lv G
    Cancer Lett; 2010 Dec; 299(2):171-81. PubMed ID: 20855150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anti-tumor role and mechanism of integrated and truncated PDCD5 proteins in osteosarcoma cells.
    Han XR; Sun Y; Bai XZ
    Cell Signal; 2012 Aug; 24(8):1713-21. PubMed ID: 22560879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme.
    Bjørnland K; Winberg JO; Odegaard OT; Hovig E; Loennechen T; Aasen AO; Fodstad O; Maelandsmo GM
    Cancer Res; 1999 Sep; 59(18):4702-8. PubMed ID: 10493528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S100A4 regulates motility and invasiveness of human esophageal squamous cell carcinoma through modulating the AKT/Slug signal pathway.
    Zhang K; Zhang M; Zhao H; Yan B; Zhang D; Liang J
    Dis Esophagus; 2012; 25(8):731-9. PubMed ID: 22458600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL.
    Pennarun B; Kleibeuker JH; Boersma-van Ek W; Kruyt FA; Hollema H; de Vries EG; de Jong S
    J Pathol; 2013 Feb; 229(3):410-21. PubMed ID: 23132258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation-associated silencing of S100A4 expression in human epidermal cancers.
    Li Y; Liu ZL; Zhang KL; Chen XY; Kong QY; Wu ML; Sun Y; Liu J; Li H
    Exp Dermatol; 2009 Oct; 18(10):842-8. PubMed ID: 19703228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
    Liu LP; Ho RL; Chen GG; Lai PB
    Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.